Evidence map›Paper›PMID 38105723›Full record

ReviewHaematologica2024

Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an <I>ad hoc</I> Italian expert panel.

Corrado Girmenia, Fabio Ciceri, Paolo Corradini, Antonio Cuneo, Fortunato D'Ancona, Pellegrino Musto, Antonio Maria Risitano, Maria Teresa Voso, Adriano Venditti, Giovanni Barosi

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Corrado GirmeniaUOSD Pronto Soccorso e Accettazione Ematologica, Department of Hematology, Oncology and Dermatology, AOU Policlinico Umberto I, Rome. girmenia@bce.uniroma1.it.
Fabio CiceriIRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan.
Paolo CorradiniUniversità degli Studi di Milano and Divisione Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano.
Antonio CuneoDivision of Hematology, University of Ferrara, Ferrara.
Fortunato D'AnconaDepartment of Infectious Diseases, Italian Institute of Health (ISS), Rome.
Pellegrino MustoHematology and Stem Cell Transplantation Unit, Azienda Ospedaliero-Universitaria-Consorziale (AOUC) - Policlinico, Bari, Italy; Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), "Aldo Moro" University - School of Medicine, Bari.
Antonio Maria RisitanoAORN San Giuseppe Moscati. Avellino.
Maria Teresa VosoHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome.
Adriano VendittiHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome.
Giovanni BarosiCenter for the Study of Myelofibrosis. IRCCS Policlinico S. Matteo Foundation, Pavia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of patients at high risk of Herpes zoster (HZ) requiring a preventive strategy with antiviral prophylaxis and anti-HZ vaccine is a clinically relevant issue in patients with immunological impairment. The absence of trials comparing vaccination to pharmacological prophylaxis or defining their sequential use makes the optimal preventive strategy uncertain. This article presents the results of group discussion among a panel of experts convened ad hoc to review the literature regarding antiviral prophylaxis and vaccine efficacy and safety in populations with malignant and non-malignant hematologic diseases, and in subjects submitted to hematopoietic stem cell transplantation. The expert panel used consensus methodology and proposed solutions for preventive strategies, producing advice for the management of the most relevant unmet clinical needs. This comprehensive overview aims to support the practice of pharmacological and vaccination-based HZ prevention and inform the design and conduct of new studies in the field.

Indexed as

Antiviral AgentsHematologic DiseasesHematopoietic Stem Cell TransplantationHerpes ZosterHerpesvirus 3, HumanHerpes Zoster VaccineHumansItalyPrecision MedicineAntiviral AgentsHerpes Zoster Vaccine

Identifiers

PMID38105723
PMCPMC11532682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.